Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study
Cancer Immunology, Immunotherapy · 06.08.2025 · 74 (9)
DOI: 10.1007/s00262-025-04136-7 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 06.08.2025. Verfasst von Hao Yu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic and Vascular Surgery, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen Universi…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Neoadjuvant Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fujian Provincial Joint Funds for Scientific and Technological Innovation Project, Natural Science Foundation of Fujian Province, Beijing Medical Awards Foundation.
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant therapy (NAT) is a promising strategy to improve long-term outcomes in hepatocellular carcinoma (HCC), particularly for patients with borderline resectable. Targeted therapy, transarterial chemoembolization (TACE), immunotherapy, and radiotherapy are all effective NAT strategies for HCC; however, the optimal NAT regimen for HCC remains undefined. METHODS: This multicentre retrospective study included 64 HCC patients who underwent NAT followed by surgical resection between 2020 and 2024 at four tertiary hospitals in China. Based on the treatment regimen, patients were divided into two groups: the dual-therapy group, which received TACE combined with either lenvatinib or bevacizumab, and the triple-therapy group, which additionally received anti-PD-1/PD-L1 immunotherapy. Survival outcomes and prognostic factors were evaluated using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: The triple-therapy group demonstrated significantly better progression-free survival (PFS) and overall survival (OS) compared to the dual-therapy group (PFS: HR = 0.450, P = 0.048; OS: HR = 0.437, P = 0.039). Multivariate Cox analysis identified triple therapy, lower tumour burden, and higher pathological response as favourable prognostic factors, whereas vascular invasion and elevated alpha-fetoprotein (AFP) levels were linked to poorer outcomes. Additionally, in this Chinese HCC cohort, the China Liver Cancer (CNLC) staging system appeared to provide superior prognostic stratification compared to the Barcelona Clinic Liver Cancer (BCLC) system. CONCLUSION: In the context of NAT for HCC, triple therapy-combining TACE, targeted agents, and immunotherapy-appears to be a more effective treatment option compared to dual therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic and Vascular Surgery, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
- Harbin Medical University Cancer Hospital, Harbin, 150000, China.
- Department of Hepatobiliary Surgery, 900th Hospital of the Joint Logistics Team, PLA, Fuzhou, 350025, China.
- Department of Hepatobiliary Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University, No. 250 East Street, Licheng District, Quanzhou, 362000, Fujian, China.
- Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian Province, Fujian Medical University Affiliated First Quanzhou Hospital, No. 250 East Street, Licheng District, Quanzhou, 362000, Fu…
- Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Förderung
- Fujian Provincial Joint Funds for Scientific and Technological Innovation Project
- Natural Science Foundation of Fujian Province
- Beijing Medical Awards Foundation
Zitieren
APA
Yu, H., Yuan, Q., Yu, R., Ye, R., Yang, S., Niu, M., Sun, Y., Ke, J., Feng, L., Guo, P., Liu, Y., Yang, J., Hong, Z., Ye, T., Ni, W., Wang, X., Xie, Z., Xu, J., Lin, C., …, & Zhan, C. (2025). Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study. Cancer Immunology, Immunotherapy, 74(9). https://doi.org/10.1007/s00262-025-04136-7
Vancouver
Yu H, Yuan Q, Yu R, Ye R, Yang S, Niu M, et al. Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study. Cancer Immunology, Immunotherapy. 2025;74(9). doi:10.1007/s00262-025-04136-7
BibTeX
@article{Yu2025,
author = {Yu, Hao and Yuan, Quan and Yu, Rui and Ye, Rongjie and Yang, Shuqi and Niu, Ming and Sun, Yunyun and Ke, Jingpeng and Feng, Liuxing and Guo, Ping and Liu, Yujian and Yang, Jingrui and Hong, Zaifa and Ye, Taozhu and Ni, Weixiang and Wang, Xin and Xie, Zhenhao and Xu, Jiahuan and Lin, Chuncheng and Lv, Lizhi and Wang, Shuangjia and Zhan, Chao},
title = {Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {9},
doi = {10.1007/s00262-025-04136-7}
}
EUVIMED